2seventy bio, Inc.
TSVT
$0.06
Change (1 day)
$6.40
Year High
$1.54
Year Low
Categories
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
P/E ratio for 2seventy bio, Inc. (TSVT)
P/E ratio as of 2023: -0.97
According to 2seventy bio, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.97. At the end of 2022 the company had a P/E ratio of -1.31.
P/E ratio history for 2seventy bio, Inc. from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.97 |
| 2022 | -1.31 |
| 2021 | -2.19 |
| 2020 | -2.32 |
| 2019 | -0.99 |
| 2018 | -1.61 |